Trial Profile
A Multicentre, Double-blind, Randomized, Placebo Controlled, Parallel Group, Phase 3, Safety Extension Study to Evaluate the Safety and Tolerability of Tezepelumab in Adults and Adolescents With Severe Uncontrolled Asthma (DESTINATION)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Nov 2023
Price :
$35
*
At a glance
- Drugs Tezepelumab (Primary)
- Indications Asthma
- Focus Adverse reactions
- Acronyms DESTINATION
- Sponsors AstraZeneca; AstraZeneca AB
- 13 Sep 2023 Results post hoc exploratory analysis assessing patients who achieved on-treatment remission over 2 years presented at the 33rd Annual Congress of the European Respiratory Society.
- 13 Sep 2023 Results presented at the 33rd Annual Congress of the European Respiratory Society
- 13 Sep 2023 Results assessing safety and efficacy of tezepelumab (210 mg every 4 weeks) in adolescents (greater than 12 less than 18 years) over 2 years presented at the 33rd Annual Congress of the European Respiratory Society